Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650697 · ClinicalTrials.gov registry record · Early Phase 1
Topical CBD Scar Outcomes Study
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
NCT05650697 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 22 participants.
The verdict
NCT05650697, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
Interventions
- BIOLOGICAL Group 1 cannabidiol (CBD) with silicone ointment
- BIOLOGICAL Group 2 silicone patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-09 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05650697
The ClinicalTrials.gov registry entry for NCT05650697 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Group 1 cannabidiol (CBD) with silicone ointment is the first listed.
NCT05650697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05650697 about?
NCT05650697 is a clinical study titled "Topical CBD Scar Outcomes Study". The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
What is the current status of trial NCT05650697?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2026-09. Estimated completion is 2027-12.
What interventions are being tested in trial NCT05650697?
The interventions under investigation include: Group 1 cannabidiol (CBD) with silicone ointment (BIOLOGICAL), Group 2 silicone patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT05650697?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.